Clinical trials
catalyst calendar across sponsors →Studies where STOK is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 11 tracked-famous managers (BAILLIE GIFFORD & CO, CITADEL ADVISORS LLC, Artisan Partners Limited Partnership, JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC, +6 more) · FINRA short interest 27.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Open-Label Extension Study of STK-001 for Patients With Dravet SyndromeNCT04740476Safety of multiple doses of zorevunersenOpen-label · Treatment | Phase 2 | Active, not recruiting | Drug: zorevunersen (STK-001) | Dravet Syndrome | 60 | 2029-03-31 | in 955 d | 2026-02-04 |
| A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeNCT06872125Measurement of Seizure ChangeRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: zorevunersen · Other: Sham Comparator | Dravet Syndrome | 170 | Mar 2027 | ≤ 224 d | 2026-08-05 |
| An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet SyndromeNCT04442295Safety and Tolerability of single and multiple doses of STK-001 with respect to:Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses | Dravet Syndrome | 62 | 2023-11-14actual | — | 2025-05-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19